Table 2.

All Treatment-Related Grade 3–5 Adverse Events (N = 35 patients)

	Total		Attributed to Avelumab		Attributed to Trabectedin		Attributed to Both
AE Term	Count	%	Count	%	Count	%	Count	%
Alanine aminotransferase increased	6	18%	0	0%	6	17%	0	0%
Lymphocyte Count Decreased	4	12%	1	3%	4	11%	1	3%
Neutrophil count decreased	3	9%	1	3%	1	3%	1	3%
Anemia	2	6%	0	0%	2	6%	0	0%
Ejection fraction decreased	2	6%	0	0%	2	6%	0	0%
Fatigue	1	3%	0	0%	1	3%	0	0%
Infusion related reaction	1	3%	1	3%	0	0%	0	0%
Aspartate aminotransferase increased	1	3%	1	3%	1	3%	0	0%
Port Infection/Inflammation/Erythema	1	3%	0	0%	1	3%	0	0%
Dyspnea	1	3%	0	0%	1	3%	0	0%
Gastrointestinal Disorders – Other	1	3%	0	0%	1	3%	0	0%
White blood cell decreased	1	3%	0	0%	1	3%	0	0%